饮酒是女性乳腺癌的主要可修改性危险因素，即使摄入量很少，对此的认识仍然很低。国家乳腺筛查计划在提供及时和有针对性的健康信息和行为改变策略以提高酒类知识水平和减少饮酒方面，具有独特的地位。乳腺筛查服务是进行简短干预的新型医疗卫生场所，具有广泛的影响潜力。本研究旨在与乳腺筛查服务消费者进行形成评估，了解乳腺筛查环境中进行简短干预（健康动画），改善饮酒知识（主要目标）、提高酒精知识水平、并减少饮酒对参加乳腺筛查的女性的影响的必要性和可接受程度，并计划合作开发简短酒类干预（Health4Her）；检测Health4Her在改善饮酒知识、提高酒类知识水平和减少乳腺筛查服务中的饮酒的有效性；并通过流程评价来检查实施策略。该研究设计的目的是评估Health4Her的有效性和实施情况，以预测和促进其在乳腺筛查服务中的推广。本研究预计将为出席乳腺筛查的女性的饮酒和识字需求以及使用新型的个性化简短酒精干预措施解决这些需求所产生的新知识提供重要的贡献。 数据采集和试验招募在2019年1月至2020年4月以及2021年2月至2021年8月进行，随访数据收集在2021年12月完成。对于试验执行数据、参与者定量（n = 497）和定性反馈（n = 30）以及场地工作人员定性反馈（n = 11）的收集已于2021年12月完成。来自乳腺筛查服务消费者的酒类消费数据的回顾性分析结果预计将于2023年3月发表，RCT的结果预计也将在同一时间发表。ClinicalTrials.gov NCT04715516；https://clinicaltrials.gov/ct2/show/NCT04715516. RR1-10.2196/44867。© Jasmin Grigg，Victoria Manning，Darren Lockie，Michelle Giles，Robin Bell，Peta Stragalinos，Chloe Bernard，Isabelle Volpe，Christopher J Greenwood，Liam Smith，Peter Bragge，Dan I Lubman。原刊于JMIR Research Protocols（https://www.researchprotocols.org），2023年3月30日。

Alcohol consumption is a major modifiable risk factor for female breast cancer, even in small amounts. However, awareness of this risk remains low. National breast screening programs are uniquely positioned to provide timely and targeted health information and behavior change strategies to improve alcohol literacy and reduce consumption. A breast screening service is a novel health care setting for brief alcohol intervention, with the potential for extensive reach.This study aimed to conduct a formative evaluation with breast screening service consumers to understand the need for, and acceptability of, brief alcohol intervention in the breast screening setting and collaboratively design a brief alcohol intervention (Health4Her); to test the effectiveness of Health4Her in improving knowledge of alcohol as a breast cancer risk factor (primary outcome), improving alcohol literacy, and reducing consumption among women attending a breast screening service; and to examine the implementation strategy through process evaluation.This was a hybrid type II effectiveness-implementation trial comprising a randomized controlled trial (RCT) alongside a mixed methods program evaluation guided by applicable elements of the Reach, Effectiveness, Adoption, Implementation, and Maintenance framework and Consolidated Framework for Implementation Research. Formative evaluation comprised a retrospective analysis of alcohol consumption data (n=49,240), a web-based survey (n=391), and focus groups and interviews (n=31) with breast screening service consumers. Women attending routine mammography, drinking at any level, were recruited to the single-site, double-blind RCT (n=558), and completed a baseline assessment before randomization (1:1) to receive Health4Her (alcohol brief intervention + lifestyle information) or control (lifestyle information) via animation on an iPad. Follow-up assessments were performed 4 and 12 weeks after randomization. The process evaluation included evaluation of trial administrative data, participant quantitative (n=497) and qualitative feedback (n=30), and site staff qualitative feedback (n=11).This research was funded in March and May 2019. Data collection for the formative evaluation and trial recruitment occurred between January and April 2020 and February and August 2021, respectively, with finalization of follow-up data collection in December 2021. Quantitative process evaluation data were collected during trial implementation, and collection of participant and staff feedback was finalized in December 2021. Results of the retrospective analysis of alcohol consumption data from breast screening service consumers is anticipated to be published in March 2023 and the results of the RCT to be published in March 2023.This study is anticipated to generate new substantial knowledge on the alcohol consumption and literacy needs of women attending breast screening and the extent to which these can be addressed using a novel, tailored brief alcohol intervention. The study design permits the evaluation of the effectiveness and implementation of Health4Her to predict and facilitate uptake in breast screening services.ClinicalTrials.gov NCT04715516; https://clinicaltrials.gov/ct2/show/NCT04715516.RR1-10.2196/44867.©Jasmin Grigg, Victoria Manning, Darren Lockie, Michelle Giles, Robin Bell, Peta Stragalinos, Chloe Bernard, Isabelle Volpe, Christopher J Greenwood, Liam Smith, Peter Bragge, Dan I Lubman. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 30.03.2023.